Ziopharm Oncology announces immuno-oncology clinical supply agreement with Regeneron
Ziopharm Oncology announced a clinical supply agreement with Regeneron to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with recurrent glioblastoma. November 12, 2018